- Home
- CUE
as 01-17-2025 4:00pm EST
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 77.3M | IPO Year: | 2018 |
| Target Price: | $5.00 | AVG Volume (30 days): | 406.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.90 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.45 - $2.93 | Next Earning Date: | 03-10-2025 |
| Revenue: | $9,532,000 | Revenue Growth: | 149.53% |
| Revenue Growth (this year): | 73.11% | Revenue Growth (next year): | 11.02% |
Stock Insider Trading Activity of Cue Biopharma Inc. (CUE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| PASSERI DANIEL R | CUE | CHIEF EXECUTIVE OFFICER | Dec 16 '24 | Buy | $1.03 | 30,000 | $30,900.00 | 164,578 |
Latest Cue Biopharma Inc. News
CUE Breaking Stock News: Dive into CUE Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
Simply Wall St.
2 months ago
Cue Biopharma Third Quarter 2024 Earnings: Beats Expectations
MT Newswires
2 months ago
Jefferies Cuts Price Target on Cue Biopharma to $4 From $6, Maintains Buy Rating
Zacks
2 months ago
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
2 months ago
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
2 months ago
Cue Biopharma Announces Strategic Organizational Transition
GlobeNewswire
2 months ago
Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
Compare CUE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CUE Cue Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.